Table 1 Baseline characteristics of the study population.
From: International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)
Missing data (n) | Quantity, median (IQR) or % | |
|---|---|---|
Age (years), median (range) | 0 | 64 (56–72) |
Gender (Male), % | 0 | 978 (49%) |
Hemoglobin (g/dL) | 54 | 12.9 (11.8–13.8) |
Creatinine (mg/dL) | 136 | 0.88 (0.71–1.04) |
Calcium (mg/dL) | 172 | 9.3 (9–9.7) |
Albumin (g/dL) | 179 | 4 (3.7–4.3) |
Beta-2 microglobulin (mg/dL) | 357 | 2.3 (1.8–3) |
Serum M-protein (g/dL) | 0 | 1.8 (1.1–2.6) |
Serum FLC ratio | 633 | 6.2 (2.1–24.1) |
Heavy-chain type | 120 | |
IgA | 452 (24.1%) | |
IgD | 6 (0.3%) | |
IgG | 1402 (74.7%) | |
IgM | 16 (0.9%) | |
Light-chain type | 24 | |
Kappa | 1199 (60.8%) | |
Lambda | 773 (39.2%) | |
Immunoparesisa | 235 | 992 (56.3%) |
Urine M-spike (mg/24 h) | 792 | 0 (0–30) |
BMPCb, higher of biopsy and aspirate % | 0 | 15 (12–25) |
